产品
编 号：F492932
分子式：C26H38N6O3
分子量：482.62
分子式：C26H38N6O3
分子量：482.62
产品类型
规格
价格
是否有货
1mg
询价
询价
5mg
询价
询价
10mg
询价
询价
结构图
CAS No: 876310-60-0
产品详情
生物活性：
RF9 is a potent and selective Neuropeptide FF receptor antagonist, with Ki values of 58 and 75 nM for hNPFF1R and hNPFF2R, respectively.
体内研究：
RF9 (0.1 mg/kg, s.c. ) with heroin coadministration prevents heroin-induced delayed hyperalgesia and tolerance.RF9 (10 μg) infused alone does not result in a significant alteration of MAP or heart rate. Conversely, MAP and heart rate increases evoked by NPFF are significantly blocked when NPFF is applied in conjunction with RF9.Animal Model:Rats.
Dosage:0.1 mg/kg.
Administration:S.C. 30 min before 0.3 mg/kg heroin or saline on basal nociceptive threshold in rats.
Result:Opposed to delaye heroin-induced hyperalgesia and associated tolerance.
体外研究：
RF9 (10 μM) pretrement completely blocks NPFF induced neurite outgrowth of Neuro 2A cells.
RF9 is a potent and selective Neuropeptide FF receptor antagonist, with Ki values of 58 and 75 nM for hNPFF1R and hNPFF2R, respectively.
体内研究：
RF9 (0.1 mg/kg, s.c. ) with heroin coadministration prevents heroin-induced delayed hyperalgesia and tolerance.RF9 (10 μg) infused alone does not result in a significant alteration of MAP or heart rate. Conversely, MAP and heart rate increases evoked by NPFF are significantly blocked when NPFF is applied in conjunction with RF9.Animal Model:Rats.
Dosage:0.1 mg/kg.
Administration:S.C. 30 min before 0.3 mg/kg heroin or saline on basal nociceptive threshold in rats.
Result:Opposed to delaye heroin-induced hyperalgesia and associated tolerance.
体外研究：
RF9 (10 μM) pretrement completely blocks NPFF induced neurite outgrowth of Neuro 2A cells.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备